 |
5 Diseases |  |
1 Trial |
|
1 Trial |  |
230 News |  |
| 123» |
- | Twymeeg (imeglimin) / Roivant
Retrospective data, Journal: Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: a systematic review and meta-analysis. (Pubmed Central) - Apr 30, 2025
Imeglimin is an effective and safe option for T2DM, particularly for improving glycemic control and ?-cell function. Further studies in diverse populations are needed to confirm these findings.
- | Twymeeg (imeglimin) / Roivant
Retrospective data, Journal: Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes. (Pubmed Central) - Apr 10, 2025
Adding imeglimin to metformin therapy demonstratedfavorable reductions in HbA1c, body weight, and FIB-4 in patients with type 2diabetes, although it was associated with the incidence of gastrointestinalAEs. UMIN000055241.
- | metformin / Generic mfg., Twymeeg (imeglimin) / Roivant
Journal: The Combination of PPAR? Agonist GW7647 and Imeglimin Has Potent Effects on High-Glucose-Induced Cellular Biological Responses in Human Retinal Pigment Epithelium Cells. (Pubmed Central) - Mar 28, 2025
UMIN000055241. The collective results suggest that Ime in combination with GW has synergetic effects on high-glucose-induced cellular biological changes in ARPE19 cells.
- | Twymeeg (imeglimin) / Roivant
Journal: Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. (Pubmed Central) - Mar 21, 2025
The collective results suggest that Ime in combination with GW has synergetic effects on high-glucose-induced cellular biological changes in ARPE19 cells. Imeglimin represents a potential new treatment option for patients with T2DM and inadequate glycaemic control with DPP-4 inhibitors, including those aged ?65?years.
- Twymeeg (imeglimin) / Roivant
Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study (Poster Area) - Mar 8, 2025 - Abstract #EASL2025EASL_2204;
- | Twymeeg (imeglimin) / Roivant
Retrospective data, Journal, Real-world evidence: A Multicenter, Retrospective Study to Evaluate the Effectiveness and Safety of Imeglimin in Patients with Type 2 Diabetes Mellitus in a Real-World Clinical Setting (Pubmed Central) - Feb 19, 2025
Imeglimin shows promise as an effective and well-tolerated option for managing T2DM in the Indian population. Also, secondary impacts of imeglimin, such as improvements in the lipid profile, hepatic function, blood pressure, and weight loss, warrant further clinical exploration.
- | Twymeeg (imeglimin) / Roivant
Journal: Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study. (Pubmed Central) - Feb 6, 2025
Imeglimin efficaciously improved liver inflammation and fibrosis in patients with T2D and MASLD, with no significant changes in liver fat content or stiffness. These findings suggest that imeglimin is a promising therapeutic drug for the management of MASLD in the context of T2D, warranting further research on its long-term efficacy and mechanisms of action.
- | metformin / Generic mfg., Twymeeg (imeglimin) / Roivant
Journal: Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study). (Pubmed Central) - Feb 6, 2025
These findings suggest that imeglimin is a promising therapeutic drug for the management of MASLD in the context of T2D, warranting further research on its long-term efficacy and mechanisms of action. Imeglimin in combination with a dipeptidyl peptidase-4 inhibitor and low-dose metformin improved HbA1c compared with metformin dose escalation.
- || Twymeeg (imeglimin) / Roivant
Review, Journal: Two Concerns and A Single Solution in Managing Type 2 Diabetes: A Narrative Review on Imeglimin. (Pubmed Central) - Feb 2, 2025
The Trials of Imeglimin for Efficacy and Safety (TIMES) program, consisting of multiple clinical trials, has substantiated the efficacy and safety of imeglimin, illustrating significant glycated hemoglobin (HbA1c) reductions and favorable safety profiles. This review synthesizes evidence from these trials, providing a comprehensive overview of imeglimin as a novel monotherapy and its compatibility in combination therapies, heralding a novel approach to T2D treatment that targets the disease's mitochondrial roots.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial. (Pubmed Central) - Jan 6, 2025
This review synthesizes evidence from these trials, providing a comprehensive overview of imeglimin as a novel monotherapy and its compatibility in combination therapies, heralding a novel approach to T2D treatment that targets the disease's mitochondrial roots. Unlike metformin, imeglimin enhances GIP secretion as well as GLP-1 secretion, in addition to its direct insulinotropic mechanism of glucose control, emphasizing its potential as a therapeutic option in the treatment of patients with diabetes.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Retrospective data, Journal: Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post-hoc analysis of imeglimin clinical trial data. (Pubmed Central) - Dec 26, 2024
Increased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Acute Effect of Imeglimin Add-on Therapy on 24-hour Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin. (Pubmed Central) - Dec 10, 2024
Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. (Pubmed Central) - Nov 27, 2024
In mitochondrial function, imeglimin improved PA-stimulated decrease in mitochondrial membrane potential, mitochondrial complexes activity, oxygen consumption rate, and mitochondrial biogenesis marker expression. In conclusion, imeglimin could contribute to prevention of MASH progression through suppressing de novo lipogenesis and enhancing fatty acid oxidation.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Biomarker, Journal: Elevated Serum Growth Differentiation Factor 15 Levels as a Potential Biomarker of the Efficacy of Imeglimin in Individuals With Type 2 Diabetes Mellitus: An Exploratory Study. (Pubmed Central) - Nov 17, 2024
Additional in vitro examination revealed that imeglimin induces GDF15 protein release from human hepatocytes. Three-month imeglimin treatment increased serum GDF15 levels in clinical type 2 diabetes mellitus patients along with little change in basal metabolism or body composition, suggesting GDF15 as a potential marker for the efficacy of imeglimin.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Mitochondrial Nephropathy with m.5538G>A Mutation within the tRNA-Trp Region Treated with Imeglimin: A Case Report () - Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5222;
Discussion. Imeglimin may be effective in MN with reduced complex III activity, but the long-term effects need to be verified..
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Rationale and Design of the Study to Investigate the Metabolic Action of Imeglimin on Patients with Type (Pubmed Central) - Sep 30, 2024
Imeglimin may be effective in MN with reduced complex III activity, but the long-term effects need to be verified.. The results of this study are expected to provide useful information for drug selection based on the pathophysiology of individual patients with type
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Molecular docking analysis of imeglimin and its derivatives with estrogen receptor-alpha. (Pubmed Central) - Sep 23, 2024
The selected derivatives showed good binding affinity with favorable pharmacokinetic profiles. The selected compounds of Imeglimin were found to possess excellent anticancer potential and could be considered as novel, cost-effective anticancer agents effective against ER positive breast cancer for further investigation.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Clinical, Retrospective data, Journal: Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data. (Pubmed Central) - Jun 26, 2024
Differences in imeglimin response were observed among T2D patient clusters. Patient stratification may help with selection of those most probable to respond to imeglimin.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Early Assessment of Imeglimin in India () - Jun 14, 2024 - Abstract #ADA2024ADA_3410;
Imeglimin shows promise as an effective treatment for T2D in the Indian context, showing efficacy across various age groups and particularly in cases of uncontrolled diabetes. Further long-term studies are recommended to assess its efficacy and safety profile over an extended period.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high-fat, high-sucrose diet-fed mice. (Pubmed Central) - Jun 14, 2024
Overall, the present results showed that imeglimin enhances glucagon secretion through an indirect mechanism. Our findings also showed that glucagon secretion promoted by imeglimin could contribute to improvement of fatty liver through suppressing de novo lipogenesis and enhancing fatty acid oxidation.
- | LY294002 / Eli Lilly, Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Imeglimin modulates mitochondria biology and facilitates mitokine secretion in 3?T3-L1 adipocytes. (Pubmed Central) - Jun 1, 2024
Our findings also showed that glucagon secretion promoted by imeglimin could contribute to improvement of fatty liver through suppressing de novo lipogenesis and enhancing fatty acid oxidation. Imeglimin modulates mitochondrial biology in adipocytes and may exert a mitohormetic effect through mitokine secretion.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Imeglimin Improves Hyperglycemia-Induced Mitochondrial Dysfunction and Increases SIRT1 and NAD+ Biosynthesis in Schwann Cells (Poster Hall (West A4-B2); 479) - May 20, 2024 - Abstract #ADA2024ADA_3116;
Furthermore, imeglimin also ameliorated the reduction in SIRT1 expression by HG. These results suggest that imeglimin may prevent diabetic neuropathy by attenuating hyperglycemia-induced mitochondrial dysfunction and cell death in Schwann cells, at least in part, through the enhancement of SIRT1 and NAD+ biosynthesis.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
The Effect of Imeglimin on Glycemic Management in Japanese Patients with Type 2 Diabetes (Poster Hall (West A4-B2); 907) - May 20, 2024 - Abstract #ADA2024ADA_2915;
OADs(number) were DPP-4i(27), SGLT2i(24), metformin(22), AGi(7) and glinides(4)(overlapped). Imeglimin increased insulin secretion, decreased BW and BFM, improved liver function and glycemic management.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Glycemic Control Enhancement with Imeglimin in Type 2 Diabetes Mellitus (Poster Hall (West A4-B2); 903) - May 20, 2024 - Abstract #ADA2024ADA_2910;
HbA1c levels showed a meaningful reduction of 0.45%. These results suggest that Imeglimin effectively enhances glycemic control in T2DM patients inadequately managed with other monotherapies.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Safety and Efficacy of Imeglimin in Patients with Metformin Intolerance (Poster Hall (West A4-B2); 894) - May 20, 2024 - Abstract #ADA2024ADA_2901;
These results suggest that Imeglimin effectively enhances glycemic control in T2DM patients inadequately managed with other monotherapies. Imeglimin show better GI tolerability as compared to metformin and significant Hba1c reduction with no effects on weight.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Response to Imeglimin for Japanese Patients with Type 2 Diabetes (Poster Hall (West A4-B2); 886) - May 20, 2024 - Abstract #ADA2024ADA_2891;
Imeglimin show better GI tolerability as compared to metformin and significant Hba1c reduction with no effects on weight. The distribution of responses to imeglimin was normally distributed and multimodal, suggesting that more than 80% of participants in the clinical trial showed substantial antidiabetic effect beyond the placebo effect.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Imeglimin, a Novel, First-in-Class Glimin Helps in Maintaining (Poster Hall (West A4-B2); 876) - May 20, 2024 - Abstract #ADA2024ADA_2880;
The distribution of responses to imeglimin was normally distributed and multimodal, suggesting that more than 80% of participants in the clinical trial showed substantial antidiabetic effect beyond the placebo effect. Imeglimin helps in maintaining ?-cell function in patients with recent-onset Latent Autoimmune Diabetes in Adults when given with insulin when compared to insulin given alone.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Imeglimin Enhances Glucose-Induced Insulin Secretion with Activating Mitochondrial Function (Poster Hall (West A4-B2); 1757) - May 20, 2024 - Abstract #ADA2024ADA_2703;
While it has been reported that the imeglimin-induced increase in GSIS in streptozotocin-treated mice is attributed to an increase in NAD+ and enhanced calcium influx by activating NAMPT expression, no change in NAD+ levels by imeglimin was observed in C57Bl/6 mice. Our data showed that a clinical relevant dose of imeglimin enhanced GSIS with enhanced mitochondrial function in islets isolated from C57Bl/6 mice.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Differential Effect of Imeglimin Compared with Metformin on Insulin and Incretin Secretion (Poster Hall (West A4-B2); 1888) - May 20, 2024 - Abstract #ADA2024ADA_1537;
Our data showed that a clinical relevant dose of imeglimin enhanced GSIS with enhanced mitochondrial function in islets isolated from C57Bl/6 mice. Although imeglimin and metformin demonstrate comparable improvement in glucose tolerance, insulinotropic effect and the effect on incretin secretion is different between imeglimin and metformin suggesting the difference of mechanism underlying their glucose-lowering effect.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study). (Pubmed Central) - May 3, 2024
Although imeglimin and metformin demonstrate comparable improvement in glucose tolerance, insulinotropic effect and the effect on incretin secretion is different between imeglimin and metformin suggesting the difference of mechanism underlying their glucose-lowering effect. No abstract available
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages. (Pubmed Central) - Apr 28, 2024
We demonstrated for the first time that imeglimin reduces LPS-induced NLRP3 inflammasome activation by inhibiting mPTP opening in THP-1 macrophages. These results suggest that imeglimin could be a promising new anti-inflammatory agent for treating diabetic complications.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ. (Pubmed Central) - Mar 24, 2024
These results suggest that imeglimin could be a promising new anti-inflammatory agent for treating diabetic complications. Imeglimin exerts favorable effects on the development of plaque formation and progression of atherosclerosis.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic ?-cells from db/db mice. (Pubmed Central) - Mar 19, 2024
Concomitantly, imeglimin and insulin, but not metformin, restored the secreted insulin level and reduced ?-cell apoptosis in db/db mice. In conclusion, imeglimin mitigated accumulation of dysfunctional mitochondria through mitophagy in diabetic mice, and may contribute to preserving ?-cell function and effective glycemic control in T2D.
- Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
THE EFFECT OF IMEGLIMIN IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS VARIES WITH THE LEVELS OF HBA1C. () - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_973;
Imeglimin significantly lowered the HbA1c level, and ameliorated serum lipids levels and hepatic function parameters in the patients. Imeglimin may have beneficial effects on glucose control, atherosclerosis and hepatic function in the diabetic patients showing poor glycemic control.However,the effect of Imeglimin in Japanese patients with type2 Diabetes Mellitus varies with the levels of HbA1c.
- Advancing Diabetes Care: Novel Drug Interventions in the Management and Control of Type 2 Diabetes Mellitus () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1668;
Over the past decade, numerous glucose-lowering medications have been approved, requiring careful consideration of their risks and benefits. It is critical to establish the strongest evidence for improving glycemic control and reducing the risk of complications .
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice. (Pubmed Central) - Mar 4, 2024
Ablation of microbiota by antibiotic treatment partially abrogated the insulin sensitizing effects of imeglimin, while not affecting its actions on body weight gain or brown adipose tissue. Collectively, our results characterize imeglimin as a potential agent promoting energy expenditure and gut integrity, providing new insights into its mechanisms of action.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. (Pubmed Central) - Feb 9, 2024
Moreover, the inhibitory effects of imeglimin on the TXNIP-NLRP3 axis depended on the imeglimin-induced activation of ULK1, which also exhibited novel anti-inflammatory effects without autophagy induction. These findings suggest that imeglimin exerted novel suppressive effects on HG-stimulated microglia through the ULK1-TXNIP-NLRP3 axis, and may, thereby, contribute to the development of innovative strategies to prevent T2DM-associated cognitive impairment.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Review, Journal: Imeglimin: the New Kid on the Block. (Pubmed Central) - Jan 15, 2024
This is a unique mode of action than has been demonstrated to be distinct from other classes of drugs, as it targets both insulin secretion and insulin resistance by correcting the mitochondrial dysfunction. Imeglimin has been studied in various phase III trials which have equivocally shown it to be effective in lowering glucose levels and improving pancreatic function and its recommended dose set at 1000 mg bid.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Clinical, Retrospective data, Review, Journal: Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials. (Pubmed Central) - Jan 3, 2024
Regrettably, there was an observed escalation in gastrointestinal AEs as the dosage of imeglimin was raised, despite the absence of a corresponding improvement in its efficacy in decreasing HbA levels. Our study suggests that imeglimin 1000?mg twice daily may offer the most optimum therapeutic effects for glycemic control without compromising its safety profiles.
- | daporinad (APO866) / Valerio Therap, metformin / Generic mfg., Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin profoundly affects the circadian clock in mouse embryonic fibroblasts. (Pubmed Central) - Nov 27, 2023
Collectively, these results reveal that imeglimin profoundly affects the circadian clock in MEFs. Further studies are needed to evaluate whether imeglimin treatment could exert similar effects in
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model. (Pubmed Central) - Oct 22, 2023
These effects were prevented by compound C or naloxone. These results suggest that imeglimin may be effective for the treatment of IBS by improved visceral sensation and colonic barrier via AMPK and opioid receptor.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Mitochondrial Dysfunction and Imeglimin: A New Ray of Hope for the Treatment of Type-2 Diabetes Mellitus. (Pubmed Central) - Oct 20, 2023
As imeglimin targets, this root cause of defective energy metabolism and insulin resistance makes it a new add-on therapy in different diabetic regimes to achieve the proper glycemic targets. Its good tolerability and efficacy profiles in recent studies shows a new ray of hope in the journey to curtail diabetes-related morbidity.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Review, Journal: Characteristics and biological properties of Imeglimin hydrochloride, A Novel antidiabetic agent: A systematic review. (Pubmed Central) - Oct 19, 2023
Its good tolerability and efficacy profiles in recent studies shows a new ray of hope in the journey to curtail diabetes-related morbidity. Therapeutic, pharmacological, and analytical considerations for the novel drug Imeglimin hydrochloride are discussed in this review.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Review, Journal: Imeglimin: A Clinical Pharmacology Review. (Pubmed Central) - Sep 26, 2023
Dosage adjustment is thus required in moderately and severely renally impaired patients. Imeglimin pharmacokinetics was shown to be insensitive to ethnicity and food intake and to have no effect on QTcF interval.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Retrospective data, Journal: Efficacy, safety and tolerability of imeglimin in (Pubmed Central) - Aug 23, 2023
Imeglimin pharmacokinetics was shown to be insensitive to ethnicity and food intake and to have no effect on QTcF interval. Imeglimin is efficacious, safe, and well tolerated as monotherapy and adjunctive therapy.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Discovery of imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents in streptozotocin-induced diabetes in Wistar rats via inhibition of DPP-4. (Pubmed Central) - Aug 18, 2023
The in vivo pharmacological assay revealed that compound 8c in a dose-dependent manner improved the insulin level, body weight, antioxidants, and HDL, and reduced the levels of blood glucose, LDL, and VLDL in streptozotocin-induced diabetes in Wistar rats. Our study demonstrated the discovery and development of novel 1,3,5-triazine derivatives bearing oxazine as a novel class of anti-diabetic agents via inhibition of DPP-4.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Preclinical, Journal: Discovery of novel 1,3,5-triazine derivatives as an antidiabetic agent in Wistar rats via inhibition of DPP-4. (Pubmed Central) - Jun 26, 2023
In experimental animals, it also showed dose-dependent improvement in blood glucose, blood insulin, bodyweight, lipid profile and kidney and liver antioxidant profiles. This study demonstrated the discovery of imeglimin-inspired novel 1,3,5-triazines as a potent antidiabetic agent.
- | Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Journal: Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial. (Pubmed Central) - Jun 23, 2023
Ethics and dissemination: The study protocol was scientifically and ethically reviewed and approved by the Certified Clinical Research Review Board of Toho University (approval number: THU22002). The study protocol was registered in the Japan Registry of Clinical Trials (jRCT) in December 2022 (jRCTs031220489).
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Clinical, Retrospective data, Journal, Monotherapy: Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials. (Pubmed Central) - Jun 2, 2023
The efficacy and safety of imeglimin was demonstrated across patient subgroups, irrespective of baseline demographic and clinical characteristics. Our findings confirm the efficacy and safety of imeglimin across a broad spectrum of patients with type 2 diabetes mellitus.
- || Twymeeg (imeglimin) / Poxel SA, Roivant, Sumitomo Pharma
Review, Journal: Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. (Pubmed Central) - May 27, 2023
Furthermore, imeglimin reduced ischemia-induced brain damage. In addition to glucose-lowering effects, imeglimin can be a useful therapeutic option for diabetic complications in type 2 diabetic patients.